{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:29:48Z","timestamp":1792459788254,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.3816\/clm.2008.s.014","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T02:03:23Z","timestamp":1229393003000},"page":"S180-S186","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S5","title":["Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas"],"prefix":"10.3816","volume":"8","author":[{"given":"Lori J.","family":"Rosenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.014_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10552-008-9147-4","article-title":"Lymphoma survival patterns by WHO subtype in the United States, 1973\u20132003","volume":"19","author":"Han","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.3816\/CLM.2008.s.014_bib3","series-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours","year":"2001"},{"key":"10.3816\/CLM.2008.s.014_bib4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib5","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/cncr.20531","article-title":"Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi","volume":"101","author":"Morabito","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.014_bib6","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib7","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V72.2.436.436","article-title":"The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype","volume":"72","author":"Lippman","year":"1988","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.1991.9.8.1426","article-title":"Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience","volume":"9","author":"Kwak","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.1989.7.6.725","article-title":"Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades\u2013should peripheral T-cell lymphoma be considered separately?","volume":"7","author":"Cheng","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cncr.22507","article-title":"Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma","volume":"109","author":"Tomita","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.014_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1042819021000030054","article-title":"Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification","volume":"44","author":"Arrowsmith","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.014_bib13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib14","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2006.06124.x","article-title":"Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study","volume":"134","author":"Sung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.014_bib18","first-page":"943","article-title":"Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen [in Chinese]","volume":"23","author":"Peng","year":"2004","journal-title":"Ai Zheng"},{"key":"10.3816\/CLM.2008.s.014_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12032-008-9046-2","article-title":"Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified","volume":"25","author":"Avil\u00e9s","year":"2008","journal-title":"Med Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.thj.6200359","article-title":"Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study","volume":"5","author":"Reimer","year":"2004","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2008.s.014_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2008.s.014_bib23","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib24","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2 suppl","key":"10.3816\/CLM.2008.s.014_bib25","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2005.12.008","article-title":"Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas","volume":"43","author":"Dearden","year":"2006","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2008.s.014_bib26","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.014_bib28","first-page":"1513","article-title":"Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes","volume":"10","author":"Dang","year":"2003","journal-title":"Oncol Rep"},{"key":"10.3816\/CLM.2008.s.014_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02983215","article-title":"Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)","volume":"77","author":"Tsukasaki","year":"2003","journal-title":"Int J Hematol"},{"key":"10.3816\/CLM.2008.s.014_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(91)80164-H","article-title":"Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia","volume":"90","author":"Kantarjian","year":"1991","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2008.s.014_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders","volume":"84","author":"O'Brien","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib32","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.014_bib34","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib35","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.014_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.014_bib37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1445-5994.2007.01397.x","article-title":"Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim","volume":"37","author":"Spencer","year":"2007","journal-title":"Intern Med J"},{"key":"10.3816\/CLM.2008.s.014_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.014_bib39","first-page":"35","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother","volume":"58","author":"Kim","year":"2006","journal-title":"Pharmacol"},{"key":"10.3816\/CLM.2008.s.014_bib40","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib41","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.014_bib43","doi-asserted-by":"crossref","first-page":"1011a","DOI":"10.1182\/blood.V110.11.3449.3449","article-title":"Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial","volume":"110","author":"Foss","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib44","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CLM.2008.s.014_bib45","first-page":"207s","article-title":"Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228","volume":"23","author":"Piekarz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.cco.0000245309.74767.20","article-title":"Pralatrexate: an emerging new agent with activity in T-cell lymphomas","volume":"18","author":"O'Connor","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2008.s.014_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2008.s.014_bib48","first-page":"3493","article-title":"Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate [published erratum appears in: Clin Cancer Res 2001; 7:1102]","volume":"6","author":"Krug","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.014_bib49","first-page":"2072","article-title":"10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer","volume":"9","author":"Krug","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.014_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O'Connor","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.014_bib51","first-page":"122a","article-title":"Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I\/II experience","volume":"108","author":"O'Connor","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib52","first-page":"752a","article-title":"Pralatrexate (10-propargyl-10-deazaaminopterin (prx)), a novel antifolate, effects durable complete remissions (cr) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity","volume":"106","author":"O'Connor","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib53","doi-asserted-by":"crossref","first-page":"412a","DOI":"10.1182\/blood.V110.11.1370.1370","article-title":"A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with hematologic malignancies","volume":"110","author":"Mould","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.014_bib54","unstructured":"Clinicaltrials.gov [Web site]. Study of pralatrexate with vitamin B12 and folic acid in patients with relapsed or refractory peripheral T-cell lymphoma. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00364923?term=propel+pralatrexate&rank=1"},{"key":"10.3816\/CLM.2008.s.014_bib55","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:37:30Z","timestamp":1709779050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":55,"alternative-id":["S1557919011702797"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.014","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}